JP2005534715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534715A5 JP2005534715A5 JP2004527741A JP2004527741A JP2005534715A5 JP 2005534715 A5 JP2005534715 A5 JP 2005534715A5 JP 2004527741 A JP2004527741 A JP 2004527741A JP 2004527741 A JP2004527741 A JP 2004527741A JP 2005534715 A5 JP2005534715 A5 JP 2005534715A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- kinds
- inhibitor
- cox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000000203 mixture Substances 0.000 claims 31
- 239000003018 immunosuppressive agent Substances 0.000 claims 10
- 150000003431 steroids Chemical class 0.000 claims 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229940111134 coxibs Drugs 0.000 claims 6
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 6
- 229940124589 immunosuppressive drug Drugs 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 5
- 108010036949 Cyclosporine Proteins 0.000 claims 5
- 108010008165 Etanercept Proteins 0.000 claims 5
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 229960001265 ciclosporin Drugs 0.000 claims 5
- 229930182912 cyclosporin Natural products 0.000 claims 5
- 229940073621 enbrel Drugs 0.000 claims 5
- YEJZJVJJPVZXGX-MRXNPFEDSA-N lefetamine Chemical compound C([C@@H](N(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 YEJZJVJJPVZXGX-MRXNPFEDSA-N 0.000 claims 5
- 229950008279 lefetamine Drugs 0.000 claims 5
- 229960000485 methotrexate Drugs 0.000 claims 5
- 229940116176 remicade Drugs 0.000 claims 5
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 5
- 229960001940 sulfasalazine Drugs 0.000 claims 5
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- -1 haloC 1 -C 6 alkyl Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims 4
- 230000001861 immunosuppressant effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 3
- 229940047495 celebrex Drugs 0.000 claims 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical group C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 3
- 229940065410 feldene Drugs 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 3
- 229940087652 vioxx Drugs 0.000 claims 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims 2
- 108010005714 Interferon beta-1b Proteins 0.000 claims 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 229940003504 avonex Drugs 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229940021459 betaseron Drugs 0.000 claims 2
- 229940038717 copaxone Drugs 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/214,897 US7067539B2 (en) | 2001-02-08 | 2002-08-07 | Cannabinoid receptor ligands |
| PCT/US2003/024398 WO2004014825A1 (en) | 2002-08-07 | 2003-08-05 | Cannabinoid receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009253551A Division JP2010024251A (ja) | 2002-08-07 | 2009-11-04 | カンナビノイドレセプタ配位子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005534715A JP2005534715A (ja) | 2005-11-17 |
| JP2005534715A5 true JP2005534715A5 (enExample) | 2006-09-14 |
Family
ID=31714260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527741A Pending JP2005534715A (ja) | 2002-08-07 | 2003-08-05 | カンナビノイドレセプタ配位子 |
| JP2009253551A Withdrawn JP2010024251A (ja) | 2002-08-07 | 2009-11-04 | カンナビノイドレセプタ配位子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009253551A Withdrawn JP2010024251A (ja) | 2002-08-07 | 2009-11-04 | カンナビノイドレセプタ配位子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7067539B2 (enExample) |
| EP (1) | EP1539662A1 (enExample) |
| JP (2) | JP2005534715A (enExample) |
| AR (1) | AR040803A1 (enExample) |
| AU (1) | AU2003257172A1 (enExample) |
| CA (1) | CA2494827A1 (enExample) |
| MX (1) | MXPA05001433A (enExample) |
| PE (1) | PE20040754A1 (enExample) |
| TW (1) | TW200413298A (enExample) |
| WO (1) | WO2004014825A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1233958B1 (en) | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP3795044B2 (ja) | 2001-09-14 | 2006-07-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CN101684091A (zh) * | 2001-11-14 | 2010-03-31 | 先灵公司 | 类大麻苷受体配体 |
| MXPA04012704A (es) * | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
| MXPA05005512A (es) | 2002-11-25 | 2005-07-25 | Schering Corp | Ligandos receptores canabinoides. |
| US7169942B2 (en) * | 2003-05-20 | 2007-01-30 | University Of Tennessee Research Foundation | Cannabinoid derivatives, methods of making, and use thereof |
| WO2005030704A1 (en) * | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2004287849A1 (en) * | 2003-10-30 | 2005-05-19 | Merck Sharp & Dohme Corp. | Aralkyl amines as cannabinoid receptor modulators |
| US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| GB2431105A (en) * | 2005-10-12 | 2007-04-18 | Gw Pharma Ltd | Cannabinoids for the treatment of pulmonary disorders |
| WO2007118137A1 (en) * | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008039645A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US8940900B2 (en) | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| CA2679373A1 (en) * | 2007-03-02 | 2008-09-12 | The University Of Tennessee Research Foundation | Tri-aryl/heteroaromatic cannabinoids and use thereof |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| CA2704684A1 (en) | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| CA2730037A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
| KR20110063485A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| JP2012529517A (ja) | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ベンジル置換トリアジン誘導体類及びそれらの治療応用 |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節するテトラゾール化合物 |
| US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
| WO2012014127A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
| KR101599300B1 (ko) | 2012-03-14 | 2016-03-03 | 시노켐 코포레이션 | 치환 디페닐아민 화합물 및 항종양제로서의 용도 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
| US4170648A (en) | 1972-05-26 | 1979-10-09 | Rohm And Haas Company | Phosphonothioureide anthelmintics |
| DE3039208A1 (de) | 1980-10-17 | 1982-05-13 | Basf Ag, 6700 Ludwigshafen | Neue sulfone, deren herstellung und verwendung |
| DE3118126A1 (de) | 1981-05-07 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Sulfenamide zur verwendung in arzneimitteln |
| US4618363A (en) | 1982-01-25 | 1986-10-21 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
| US4468389A (en) | 1982-05-21 | 1984-08-28 | Rohm And Haas Company | Pesticidal N-sulfonyl phosphorodiamido(di)thioates |
| US4466965A (en) | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
| US4567184A (en) | 1982-12-01 | 1986-01-28 | Usv Pharmaceutical Corporation | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies |
| NZ213986A (en) | 1984-10-30 | 1989-07-27 | Usv Pharma Corp | Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such |
| US4781866A (en) | 1985-03-15 | 1988-11-01 | Mcneilab, Inc. | Process for producing amidine sulfonic acid intermediates for guanidines |
| US4678855A (en) | 1985-10-09 | 1987-07-07 | Merck & Co., Inc. | Substituted benzenesulfonamides |
| SK219587A3 (en) | 1986-03-31 | 1997-06-04 | Rhone Poulenc Bv | Agent for plants growth control |
| HU201448B (en) | 1986-03-31 | 1990-11-28 | Rhone Poulenc Bv | Plant growth reducing compositions comprising malonic acid derivatives and process for producing new malonic acid derivatives |
| DE3634927A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von sulfonylisothioharnstoffen |
| DE3634926A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von o-aryl-n'-pyrimidin-2-yl-isoharnstoffen |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| NZ232493A (en) | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
| US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| IE902465A1 (en) | 1989-07-07 | 1991-02-13 | Schering Corp | Pharmaceutically active compounds |
| IT1240676B (it) | 1990-04-24 | 1993-12-17 | Agrimont Spa | Composizioni ad attivita' erbicida |
| NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| US5332820A (en) | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
| JPH0672979A (ja) | 1992-06-08 | 1994-03-15 | Hiroyoshi Hidaka | アミノベンジル誘導体 |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| GB9218834D0 (en) | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
| AU7100394A (en) | 1993-06-17 | 1995-01-17 | Dunlena Pty. Limited | Arthropodicidal sulfonates |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| DK0754672T3 (da) | 1994-04-06 | 2000-11-13 | Shionogi & Co | Gamma-Substitueret phenyleddikesyrederivat, fremgangsmåde til fremstilling deraf og landbrugsfungicid indeholdende samme |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| BR9607016A (pt) | 1995-02-02 | 1997-10-28 | Smithkline Beecham Plc | Derivados de indol como antagonísta de receptor 5-ht |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| ATE196629T1 (de) | 1995-07-21 | 2000-10-15 | Nycomed Austria Gmbh | Derivate von benzosulfonamiden als hemmer des enzym cyclooxygenase ii |
| DE19533644A1 (de) | 1995-09-12 | 1997-03-13 | Nycomed Arzneimittel Gmbh | Neue Benzolsulfonamide |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| HUP9904167A3 (en) * | 1996-07-01 | 2000-07-28 | Schering Corp | 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same |
| SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
| JP2001500864A (ja) | 1996-09-13 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | トロンビン阻害物質 |
| JP2001508799A (ja) * | 1997-01-21 | 2001-07-03 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体モジュレータ |
| ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| CA2283797A1 (en) | 1997-03-18 | 1998-09-24 | Paul Elliot Bender | Novel cannabinoid receptor agonists |
| WO1999021851A1 (en) | 1997-10-24 | 1999-05-06 | Nissan Chemical Industries, Ltd. | Sulfamoyl compounds and agricultural or horticultural bactericide |
| WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| CN1142909C (zh) | 1998-03-26 | 2004-03-24 | 盐野义制药株式会社 | 具有抗病毒活性的吲哚衍生物 |
| JP2002521436A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | 置換アニリド化合物および方法 |
| WO2000056707A1 (en) | 1999-03-24 | 2000-09-28 | Sepracor, Inc. | Diaryl thioethers, compositions and uses thereof |
| DE60038687T2 (de) | 1999-09-14 | 2009-05-28 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazin-derivate |
| MXPA02005101A (es) * | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
| ES2311479T3 (es) | 1999-11-26 | 2009-02-16 | SHIONOGI & CO., LTD. | Antagonistas de npy-y5. |
| WO2001044172A1 (en) | 1999-12-15 | 2001-06-21 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease and factor xa inhibitors |
| WO2001044239A2 (en) | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2003528106A (ja) | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
| AU2001253147A1 (en) | 2000-04-03 | 2001-10-15 | Phycogen, Inc. | Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins |
| MXPA02010693A (es) | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
| WO2001087293A1 (en) | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | -secretase inhibitors |
| GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| CN101684091A (zh) | 2001-11-14 | 2010-03-31 | 先灵公司 | 类大麻苷受体配体 |
| FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| MXPA04012704A (es) * | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
-
2002
- 2002-08-07 US US10/214,897 patent/US7067539B2/en not_active Expired - Fee Related
-
2003
- 2003-08-05 CA CA002494827A patent/CA2494827A1/en not_active Abandoned
- 2003-08-05 MX MXPA05001433A patent/MXPA05001433A/es active IP Right Grant
- 2003-08-05 PE PE2003000774A patent/PE20040754A1/es not_active Application Discontinuation
- 2003-08-05 JP JP2004527741A patent/JP2005534715A/ja active Pending
- 2003-08-05 EP EP03784905A patent/EP1539662A1/en not_active Withdrawn
- 2003-08-05 AU AU2003257172A patent/AU2003257172A1/en not_active Abandoned
- 2003-08-05 WO PCT/US2003/024398 patent/WO2004014825A1/en not_active Ceased
- 2003-08-06 AR AR20030102821A patent/AR040803A1/es unknown
- 2003-08-06 TW TW092121502A patent/TW200413298A/zh unknown
-
2009
- 2009-11-04 JP JP2009253551A patent/JP2010024251A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005534715A5 (enExample) | ||
| JP2004530649A5 (enExample) | ||
| CA2436659A1 (en) | Cannabinoid receptor ligands | |
| CN100496493C (zh) | 2-氨基-4,5-三取代噻唑基衍生物 | |
| CN100502863C (zh) | 2,4,5-三取代噻唑衍生物和它们的抗炎活性 | |
| JP6938561B2 (ja) | 重水素化２，４−チアゾリジンジオン及び治療方法 | |
| EP3768667B1 (en) | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| JP6845231B2 (ja) | Ｂ型肝炎抗ウイルス薬の結晶形態 | |
| JP2017510643A5 (enExample) | ||
| JP2017505808A5 (enExample) | ||
| JP2017510644A5 (enExample) | ||
| JP2017510642A5 (enExample) | ||
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| EP2455370A1 (en) | Pharmaceutical product containing lactam or benzene sulfonamide compound | |
| AU2018203833A1 (en) | Tetracyclic bromodomain inhibitors | |
| JP2020537657A5 (enExample) | ||
| CN101365699A (zh) | 吡啶并(3,2-d)嘧啶和可用于医疗的药物组合物 | |
| JP2018534326A5 (enExample) | ||
| JP2008503585A5 (enExample) | ||
| JO2482B1 (en) | Amide compounds by replacement | |
| JP2010540602A5 (enExample) | ||
| JPWO2018181883A1 (ja) | ４−ピリドン化合物またはその塩、それを含む医薬組成物および剤 | |
| TW201249829A (en) | Bipyridylaminopyridines as Syk inhibitors | |
| RU2014131378A (ru) | Ингибиторы бромдомена | |
| WO2011032277A1 (en) | Quinazolinone derivatives as viral polymerase inhibitors |